T cell Engagers Program

About Shennon Biotechnologies

Shennon Biotechnologies is a private, preclinical-stage biotech founded in 2018 and headquartered in San Francisco, CA. The company has developed the TCELERATOR™ platform, which combines ultrafast functional screening of single-cell interactions with proprietary AI models to identify novel therapeutic targets and agents, primarily in immuno-oncology and autoimmunity. Backed by a $13M seed round and a team with deep expertise in immunology, single-cell analysis, and drug development, Shennon aims to de-risk and accelerate early-stage drug discovery by moving from phenotypic screening directly to target identification and candidate building.

Therapeutic Areas

Other Cancer Drugs